Synact in Media

March 2023

Company presentation

December 20, 2022

BioStock: Interview regarding TXP

December 12, 2022

Presentation related to TXP Acquisition and Directed Share Issue

November 4, 2022

BioStock: Interview with CSO Thomas Jonassen

October 10, 2022

BioStock: SynAct submits IND and recruits first patient in phase 2b.

September 20, 2022

SynAct Pharma wins two awards at GHP 2022

July 12, 2022

Listing ceremony Nasdaq Stockholm

June 9, 2022

Presentation at BioStock Life Science Spring Summit

June 1, 2022

Presentation at Life Science Investor Konference, June 1, 2022 – Copenhagen

May 2, 2022

Presentation at Aktiedagen Stockholm May 2, 2022

April 25, 2022

Presentation at Sedermeradagen April 25, 2022

April 6, 2022

BioStock: SynAct Pharma’s CEO on the rights issue and partnering discussions

March 28, 2022

Interview with Direct Studios

March 28, 2022

Presentation regarding the Rights Issue 2022

February 14, 2022

BioStock: SynAct Pharma well positioned for an eventful 2022

December 10, 2021

SynAct discusses AP1189 with Sedermera

December 10, 2021

MedWatch: Synact Pharma vil intensivere partner-drøftelser

December 7, 2021

SynAct discusses AP1189 Phase 2a results with Direkt

December 3, 2021

BioStock Studio: SynAct Pharma comments on the promising study results in RA

November 30, 2021

SynAct Pharma’s AP1189 meets primary endpoint – Nordic Life Science – the leading Nordic life science news service

November 30, 2021

Scrip: SynAct Surveys Its Options As Rheumatoid Arthritis Asset Succeeds At Phase II

November 11, 2021

BioStock: SynAct Pharma’s CSO and CMO comment on clinical development

July 28, 2021

Nordic Life Science News: SynAct Pharma announces positive additional trial data

June 30, 2021

DagensPS: Lungfunktion vid Covid-19 förbättras med svensk läkemedelskandidat

June 17, 2021

Healthcare Direkt v. 24 l Synact Pharma om kommande fas 2-resultat

February 5, 2021

Finwire – En tydlig utvecklingsplan för AP1189 stärker förhandlingspositionen

November 11, 2020

SynAct Pharma mentioned in the Rheumatoid Arthritis (RA) – Pipeline Insight, 2020

September 23, 2020

DI (Nyhetsbyrån Direkt): Synact Pharma startar fas 2-studie med covid-patienter

September 22, 2020

BIOSTOCK: SynAct Pharma sees potential in several viral diseases

September 22, 2020

BIOSTOCK: SynAct Pharma ser potential inom flera virussjukdomar

July 3, 2020

Cision Promoted: Emission teckningsoptioner ska driva två projekt genom fas II

June 30, 2020

Aktiespararna: Intensiv höst med sikte på utlicensiering i horisonten

June 2, 2020

BIOSTOCK: SynAct närmar sig studiestart efter myndighetsgodkännande

May 12, 2020

Redeye: Interview with CEO Jeppe Øvlesen and CSO Thomas Jonassen (video call)

May 6, 2020

BIOSTOCK: SynAct comments on positive Phase II data

April 2, 2020

BIOSTOCK: Synact Pharma on expansion into Covid-19

April 2, 2020

BIOSTOCK: SynAct Pharma om Covid-19-satsningen (in Swedish)

April 1, 2020

Synact Pharma in spotlightanalysen (in Swedish)

April 1, 2020

Medwatch: Synact rekrutterer fortsat til forsøg trods pandemi (in Danish)

March 31, 2020

Life Science Sweden: Vill dämpa lunginflammationen vid covid-19 (in Swedish)

March 31, 2020

Medwatch: Synact Pharma vil teste hovedkandidat som tillægsbehandling til coronasyge patienter (in Danish)

March 31, 2020

Dagens Industri: Spotlight-bolag planerar preparattester på coronapatienter (in Swedish)

December 6, 2019

Medwatch: Synact Pharma kommer i mål med aktieemission – overtegnet med 295 pct (in Danish)

November 12, 2019

Medwatch: Synact får grønt lys til forsøg i Sverige (in Danish)

October 21, 2019

Medwatch: Biotekselskab vil starte nyt forsøg med hovedaktiv og udsteder aktier for millioner (in Danish)

June 28, 2019

Medwatch: Biotekchef lander ny bestyrelsespost efter hjemtur til Danmark (in Danish)

April 1, 2019

Medwatch: Synact ready for phase II with arthritis candidate: “An important milestone for the company”

April 1, 2019

Medwatch: Synact er klar til fase 2 med gigthåb: “En stor milepæl for selskabet” (in Danish)

February 11, 2019

Medwatch: Synact skal rejse 14 mio kr til nyt forsøg med hovedkandidat (in Danish)

August 21, 2018

Medwatch: Synact Pharmas hovedkandidat viser lovende takter mod sjælden nyresygdom (in Danish)

May 12, 2018

Medwatch: Synact Pharma fordobler svensk kapitalrejsning (in Danish)